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Abstract
The ribosome is an RNA-protein complex essential for translation in all domains of life. The structural
and catalytic core of the ribosome is its ribosomal RNA (rRNA). While mutations in ribosomal protein
(RP) gene are known drivers of oncogenesis, oncogenic rRNA variants have remained elusive.
We discovered a cancer-specific single nucleotide variation at 18S.1248U in the 18S rRNA of up to
45.9% colorectal carcinoma (CRC) patients and across >22 cancer types. This is the site of a unique
hyper-modified base, 1-methyl-3-α-amino-α-carboxyl-propyl pseudouridine (m1acp3Ψ), a modification), a modification
that is >1 billion years conserved at the ribosome’s peptidyl decoding-site. A sub-set of CRC tumors we
term ‘hypo-m1acp3Ψ), a modification’, show sub-stoichiometric m1acp3Ψ), a modification-modification unlike normal control tissues.
Our  m1acp3Ψ), a modification  knockout  model  and  hypo-m1acp3Ψ), a modification  patient  tumors  share  a  translational  signature,
characterized by highly abundant ribosomal proteins.
Thus, m1acp3Ψ), a modification-deficient rRNA forms an uncharacterized class of ‘onco-ribosome’ which may serve as
an innovative chemotherapeutic target for treating cancer patients.
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Introduction
The ribosome is  a  massive  ribonucleoprotein  particle  (RNP) responsible  for  the  transformation  of
genetic information encoded as nucleic acids into functional proteins encoded as amino acids. Unlike
most RNPs, it is ribosomal RNA (rRNA), and not ribosomal proteins (RPs) that form the most ancient
and catalytic core of the complex1. rRNA is further functionalized by a constellation of at least 14
distinct chemical modifications across 200+ sites,2 clustering around active sites of the ribosome3, yet
the function of many rRNA modifications remain unclear. 
The human ribosome contains >80 RPs and four rRNAs, totaling ~80% of cellular RNA. During the
initial human genome sequencing project, ribosomal DNA (rDNA) loci were systematically excluded
from the reference genome4; given that a reference sequence of the rRNA gene, RNA45S, was available
and the 80-800 rDNA copies were believed to be homogeneous5, although there was early evidence for
rDNA  polymorphism  in  humans6,7.  Thus,  as  technology  and  sequencing  consortium  projects
revolutionized genomics and transcriptomics, our understanding of rDNA variation has lagged.
rDNA sequence  variation  at  the  intra-  and inter-individual  level  has  been documented  in  multiple
species  including  humans8–12,  but  the  functional  implications  of  rDNA variation  remain  elusive.
Mutation  of  RP  genes  and  ribosome  biogenesis  factors  can  cause  a  class  of  diseases  termed
ribosomopathies,  including  Diamond  Blackfan  anemia  (DBA)13,  and  some  cancers14.  It  has  been
hypothesized that cancer cells contain a functionally specialized class of ribosomes to facilitate rapid
protein synthesis, termed the “onco-ribosomes”15,16. Cancer genomics has supported this notion with the
identification of several oncogenic driver mutations in RP genes14, the best characterized of which are
RPL10  (uL16)  p.R98S  in  T-cell  acute  lymphoblastic  leukemia17,18 and  RPS15  (uS19)  C’ terminal
mutations in chronic lymphocytic leukemia19. In addition, germline mutations such as in DBA patients
and in RPS20 can cause heredity cancers including colorectal carcinoma (CRC)20,21.
As RP mutations  have  been implicated  in  tumorigenesis,  we hypothesized  that  rRNA variation  or
mutation is a cancer driver. To map functional rRNA sequence variation, we considered tumorigenesis
as a natural experiment in which polymorphic and mutant rRNA alleles undergo selective evolutionary
change in  frequency within  each patient.  We discovered  a  surprising  18S rRNA single  nucleotide
variation at the decoding core of the ribosomal peptidyl (P)-site, affecting up to 45.9% of CRC patients,
making  this  the  most  frequent  ribosomal  variant  associated  with  cancer  to  date  and  potentially
revolutionizing future chemotherapeutic strategies against this disease.
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Results & Discussion
An unexpected rRNA variant in cancer: sub-stoichiometric modification of 18S.1248.m1acp3Ψ
In an initial screen for cancer-driver rRNA variants, we aligned RNA-seq reads from 66 colorectal
carcinoma (CRC) tumors and patient-matched adjacent normal tissue to a single-copy reference rDNA.
To test for allelic selection inconsistent with neutral drift, the patient-matched difference in expressed
variant allele frequency (VAF) was measured for deviation from zero for each position of 18S and 28S
(Fig. 1a).  A single nucleotide variation deviated from neutrality,  18S:r.1248.U (padj = 3.81e-8). The
18S.1248.U variation is recurrent selection over non-U or 18S.1248V alleles in a striking 44.9% of
CRC patients (Fig. 1a); in comparison, oncogenic KRASG12 codon mutation occurs in only 36% of CRC
patients22.
Surprisingly, at the DNA level, RNA45S:1248.T is invariable in humans10 and in the mature rRNA this
uridine  undergoes  hyper-modification  to  1-methyl-3-α-amino-α-carboxyl-propyl  pseudouridine
(m1acp3Ψ), a modification) (Fig. 1b)2. The m1acp3Ψ), a modification modification perturbs standard Watson-Crick base-pairing during
cDNA synthesis by reverse transcriptase (RT)23, resulting in base misincorporation and enzyme stalling,
which is read-out as a consistent ‘modification signature’ in RNA-seq (Fig. 1c, reviewed in  23). The
increase  in  reference  U  sequence  suggests  that  the  m1acp3Ψ), a modification  modification  is  incomplete  or  sub-
stoichiometric in CRC tumors, which we term the ‘hypo-m1acp3Ψ), a modification phenotype’. The 28S.1321.m1A and
28S.4532.m3U  rRNA  modifications  also  cause  a  ‘modification  signature’  in  RNA-seq23.  These
modifications do not decrease in CRC tumors or matched normal controls, excluding a non-specific
rRNA modification effect (Fig. 1d).
The hypo-m1acp3Ψ), a modification phenotype is reproducible at comparable frequency (27.8-45.9%) in three additional
independent  patient-matched CRC cohorts  (Fig.  1e,f).  Analysis  of  10,036 cancer  patients  and 712
normal controls across an additional 31 cancer-patient cohorts reveals that hypo-m1acp3Ψ), a modification occurs at a
significant frequency across a diverse set of cancers, but is not pan-cancerous (global recurrence: 9.6%
range: 0-52.8%) (Fig. 1f, S1).
To validate  these findings,  we designed a simple and rapid RT-PCR  m1acp3Ψ), a modification assay for measuring
18S.1248.m1acp3Ψ), a modification modification.  The  m1acp3Ψ), a modification assay is  reproducible and quantitative (Fig.  S2).  An
important technical limitation is that different RT enzymes have different base misincorporation rates at
18S.1248.m1acp3Ψ), a modification, thus, cross-cohort or cross-experimental comparisons should be made cautiously,
including in RNA-seq (Fig. S2b-d). Indeed, batch-effects on VAF are seen within TCGA cohorts, but
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hypo-m1acp3Ψ), a modification replicates across batches, further supporting that hypo-m1acp3Ψ), a modification is occurring in tumors
specifically (Fig. S1b).
We validated that the hypo-m1acp3Ψ), a modification  phenomenon also occurs in CRC cell lines assayed as a single
batch and confirmed the results are not a sequencing artifact (Fig. S2e). To test if  m1acp3Ψ), a modification-deficient
rRNA incorporate into mature ribosomes, we isolated monosomes and polysomes and detected low
m1acp3Ψ), a modification modification  levels  in  mono-  and  di-somes  (Fig.  S2f). As  the  molecular,  biological,  and
medical significance of 18S.1248.m1acp3Ψ), a modification unfolds, it is obvious that genotyping technologies (such as
sequencing or  our  m1acp3Ψ), a modification assay)  and previous  m1acp3Ψ), a modification assays  such as  primer  extension  can  be
adapted as affordable and rapid diagnostic or prognostic assays.
18S:1248.m1acp3Ψ is an ancient modification at the P-site core
We next investigated the evolutionary and structural characteristics of 18S.1248.m1acp3Ψ), a modification for functional
insight. The 18S:1248.U base and m1acp3Ψ), a modification modification are absolutely conserved across Eukarya at a
residue located in the loop of universal helix 31 (Fig. S3). TSR3 is the aminocarboxylpropyl transferase
which deposits the acp3 at 18S.1248.U24 and it only modifies this single rRNA position, in 100% of
mature rRNA molecules25,26.
Structurally, 18S.1248.m1acp3Ψ), a modification is solvent-exposed at the ribosomal P-site, immediately adjacent to the
codon:anti-codon  interface  (Fig.  2).  Cryo-EM  structures27,28 and  our  molecular  dynamics  (MD)
simulations  implicate  the  m1acp3-modification  in  a  direct  interaction  with  P-site  tRNA with  the
carboxyl-moiety  forming  a  hydrogen  bond  with  the  universally  conserved  RPS16  p.R14629 and
reducing 18S rRNA flexibility at the decoding site (Fig. S4).
Start AUG-codon selection and translational initiation is a rate-limiting step in protein-synthesis and
both occur at the P-site. Thus, the hypo-m1acp3Ψ), a modification phenotype may demarcate a class of ‘onco-ribosome’
with deregulated translation. It is noteworthy that the two largest effect size RP cancer driver mutations
also occur at the ribosomal P-site/tRNA interface, the RPL10 p.R98S at the peptidyl transfer site17,18
and RPS15 C` tail mutations adjacent (<12Å) to 1248.m1acp3Ψ), a modification (Fig. 2a) suggesting that the ribosomal
P-site is a convergent multi-cancer oncogenic hot-spot.
Since the discovery of streptomycin in 1944, the ribosome has been the target of several important
classes of drugs30. The pervasive and recurrent loss of a solvent-exposed and charged acp3 modification
at the decoding core of the small sub-unit raises the possibility that this pocket may be therapeutically
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exploited  with  ribosome  targeting  antibiotics  or  their  derivatives  as  a  new  generation  of
chemotherapies.
Loss of 18S.1248.m1acp3Ψ modification induces ribosomal protein mRNA translation
To  delineate  the  function  of  18S.1248.m1acp3Ψ), a modification,  we  generated  TSR3  knockout  CRC  cell  lines
(HCT116). Similar to yeast24, TSR3 is non-essential and we isolated two TSR3 homozygous knockouts
(TSR3[KO 1,3]),  a heterozygous knockout (TSR3[Het 2]),  as well  as three wildtype control clones
(WT[1-3]).  Knockouts  were  functionally  confirmed  by  three  independent  m1acp3Ψ), a modification  assays,  with
TSR3[Het 2] showing an intermediate or hypo-m1acp3Ψ), a modification phenotype (Fig. 3a, S2g). Loss of the acp3
modification via TSR3[KO] is sufficient to abolish nucleotide misincorporation during RT as measured
by RNA-seq, supporting hypo-m1acp3Ψ), a modification tumors contain sub-stoichiometric loss of the acp3-moiety.
Morphologically, the HCT116 clones were indistinguishable and showed comparable, rapid growth in
vitro (Fig. 3b). To determine how loss of 18S.1248.m1acp3Ψ), a modification modification affects the transcriptome and
translatome of these cells we performed RNA-seq and ribo-seq, respectively (Fig. S5).
Transcriptionally, gene set enrichment analysis (GSEA) revealed that TSR3[KO]/[Het] (vs. WT) cells
were  dominated  by  a  proliferative  tumor  expression  signature,  characterized  by  elevated  E2F
transcription  factor  activity  (Fig.  3c,  Fig.  S6,  table  S3).  Yet,  TSR3[KO]/[Het]  cells  also  have  a
paradoxical decrease in translational efficiency of the same E2F target genes (Fig. S6).
To determine how loss of 18S.1248.m1acp3Ψ), a modification modification alters translation, we contrasted translational
efficiency between genotypes. TSR3[KO]/[Het] cells showed a remarkable enrichment (vs. WT) in the
translation of RPs and associated with a depletion of RP mRNA (Fig. 3d).
To validate if this RP mRNA/protein signature is present in patients, we analyzed the CPTAC-CRC
cohort  with tumor matched RNA-seq and proteomics data31.  Similar  to  TSR3[KO]/[Het]  cell  lines,
hypo-m1acp3Ψ), a modification CRC tumors share the same E2F oncogenic gene signature and a proteomic increase in
RPs relative to normo-m1acp3Ψ), a modification CRC tumor controls (Fig. 3e,f).
There are two hypotheses with which to interpret the hypo-m1acp3Ψ), a modification phenotype. The ‘oncogenic driver
hypothesis’ is that m1acp3Ψ), a modification-deficient rRNA arise in tumorigenesis, and their dysregulated translation
confers  a  selective  advantage  to  the  cancer,  likely  via  high  RP output.  The  recapitulation  of  the
TSR3[KO]/[Het]  multi-omic  phenotype  in  hypo-m1acp3Ψ), a modification  CRC  patients  supports  a  causal  model.
Alternatively,  m1acp3Ψ), a modification-deficiency  arises  in  consequence  to  hyper-proliferation  and  high  ribosomal
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biogenesis. Rapid cellular turn-over in turn results in ‘incomplete modification’ of rRNA. Under this
model the consequences of m1acp3Ψ), a modification-deficient rRNA is near-neutral or tolerably detrimental to tumor
fitness. Nevertheless, hypo-m1acp3Ψ), a modification is a highly recurrent pertubation to the ancient peptidyl-decoding
core and underlies a greater cancer-translational phenomenon.
Conclusions
Ribosomes  are  the  fulcrum in  the  central  dogma  of  molecular  biology.  Multi-omics  studies  have
repeatedly highlighted the discordance between mRNA and protein abundance32,33,  emphasizing the
role of translational variability in physio-normal and pathological states. Several recent studies have
begun  to  resolve  the  ribosome  from  a  uniform  assembly  into  a  rich  tapestry  of  functionally
heterogeneous complexes making up distinct translational compartments in the cell15,16,34–37. We have
discovered  a  pervasive  and  cancer-specific  ‘onco-ribosome’  marked  by  loss  of  rRNA m1acp3Ψ), a modification
modification. Enticingly, the cancer-specific m1acp3Ψ), a modification-deficient ribosomes are exceptionally recurrent
and can be explored as a novel chemotherapeutic class.
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Figure 1: The hypo-m1acp3Ψ phenotype in cancer
a i, Screen for change in the average variant allele frequency (VAF) across  18S  and  28S ribosomal
RNA (rRNA) in colorectal cancer (CRC) RNA-seq compared to patient-matched normal epithelium
controls (n = 69). Read coverage and quality drops at extreme GC-content (>90%) regions of 28S,
these  low-coverage  regions  were  excluded  from  further  analysis.  ii, The  common  human  rRNA
polymorphism  28S:r.59G>A ranges  from  0.05–0.93  DNA allele  frequency10 and  was  expressed
compatibly in the normal epithelium between variant allele frequencies (VAF) of 0.01-0.86. Neither
allele is directionally selected for during cancer evolution, consistent with neutral drift (padj  = 1, t = -
0.44). iii, 18S:r.1248.U is significantly enriched (padj  = 3.81e-8, t = 8.33) for the reference U allele. b,
The 18S:r.1248.U base normally undergoes enzymatic hyper-modification to 1-methyl-3-α-amino-α-
carboxyl-propyl pseudouridine (m1acp3Ψ), a modification) in three steps;  SNORA13 guided pseudouridylation; EMG1
N1-methylation; and finally 3-amino-carboxyl-propylation by TSR3.  c, Perturbation of the Watson-
Crick face of the modified base results in a distinct nucleotide misincorporation signature by reverse
transcriptase in first strand cDNA synthesis, which is read out on both the sense (+) and anti-sense
strand (-) of sequencing. d, Patient 18S:r.1248.m1acp3Ψ), a modification hypo-modification is defined as a decrease in
VAF by three standard deviations (3σ) of the matched-normal samples. Hypo-m) of the matched-normal samples. Hypo-m1acp3Ψ), a modification is not correlated
with the loss of other rRNA modifications detectable by RNA-seq. e, The hypo-m1acp3Ψ), a modification phenotype is
replicated  in  three  additional,  independent  cohorts  of  CRC with  patient-matched  adjacent  normal
controls, including two cohorts from The Cancer Genome Atlas (TCGA), colorectal adenocarcinoma
(COAD) and rectal adenocarcinoma (READ). f, Hypo-modification of 18S:r.1248.m1acp3Ψ), a modification is prevalent
but  not ubiquitous  across the TCGA cancer  cohorts  (n = 10,078 patients)  and largely absent  from
patient-matched normal controls (n = 708) (see: Fig. S1).
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Figure 2: 18S:1248.m1acp3Ψ is located at the peptidyl decoding site
a, The  mRNA channel  of  the  human  small  sub-unit  (SSU) cryo-EM structure  with  resolved base
modifications (PDB: 6EK027). The 18S:1248.m1acp3Ψ), a modification (red) nucleotide is on the loop of the universal
helix 31, exposed to the mRNA channel at the center of the P-site. The CLL driver mutations in the
RPS15 C` tail (green) are <12.8Å from 18S:1248.m1acp3Ψ), a modification. The minimal distance is likely shorter as
the 10 terminal residues of RPS15 which extend into the P-site are labile and not modeled. b, Cryo-EM
structure with a P/E-site tRNA, 18S.1248.Ψ), a modification and 18S.1701.C base stack with the ribose and base of the
tRNA.34.C,  respectively  (PDB:  6OLE28).  18S.1248.m1acp3Ψ), a modification  modification  contributes  to  P-site
decoding site stability via interaction with P-site tRNA and RPS16 (Fig. S4).
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Figure 3: The translational signature of  m1acp3Ψ-deficient ribosomes
a  i, Reverse  transcription  (RT)-PCR  m1acp3-assay  (see:  methods  and  Fig.  S2)  and  ii, RNA-seq
measurement for nucleotide misincorporation at 18S:1248.m1acp3Ψ), a modification in clones of the colorectal cancer
HCT116 cell line with HUVEC as a normal positive control.  b, The fold-change growth of HCT116
clone populations in culture, normalized to cells at 24 hours.  c,  Summary of Gene Set Enrichment
Analysis (GSEA) of RNA-seq comparing HCT116 WT[1-3] versus HCT116  TSR3[KO 1,3 / Het 2]
clones. Only significant (False Discovery Rate Q-value < 0.05) gene sets in the Oncogenic Signature
collection are shown. d, TSR3[KO/Het] cells GSEA shows no change in ribosomal protein (RP) mRNA
abundance, while RP translational efficiency increases.  e,  CPTAC colorectal carcinoma (CRC) tumor
GSEA shows a similar increase in RP protein abundance. f, Summary of Oncogenic Signature GSEA
comparing  CPTAC-CRC tumors  with  normo-m1acp3Ψ), a modification  and  hypo-m1acp3Ψ), a modification  modification.  Gene  sets
common to HCT116 TSR3[KO]/[Het] and hypo-m1acp3 CPTAC-CRC patients are bolded.
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Data and code availability
Sequencing data generated in this study is available on NCBI SRA (pending accession). Electronic
laboratory notebook for these experiments and analysis scripts are available at https://www.github.com/
ababaian/  C  rown  .
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Supplementary Figure 1: Detailed look at  hypo-m1acp3Ψ in the TCGA cohorts
a, The 18S.1248.U variant allele frequency (VAF) from 33 TCGA patient cohorts (study abbreviations
in table S1). b Batch-specific shift in the average 18S.1248.U VAF in i, TCGA-COAD and ii, TCGA-
DLBC libraries. Similar to seen in the RT-PCR m1acp3Ψ), a modification assay (figure S2), there are batch-effects with
m1acp3Ψ), a modification misincorporation,  but the relative decrease in  m1acp3Ψ), a modification-modification in CRC compared to
normals is seen in across all batches. c, The gene expression of the m1acp3Ψ), a modification modifying enzymes TSR3
and EMG1 is not decreased or lost across the TCGA cohorts.
Supplementary Figure 2: RT-PCR  m1acp3Ψ assay and rRNA modification in cell lines
a i, The 18S.1248.m1acp3Ψ), a modification modification assay is based on the misincorporation of nucleotides in first
strand complementary DNA (cDNA) strand synthesis by reverse transcriptase (RT). The cDNA is then
PCR amplified and ii,  the ratio of reference T and not-T (V = A, C, or G) is genotyped by the HinFI
restriction enzyme cut-site which overlaps 18S.1248.  b,  The choice of RT-enzyme; SuperScript III
(SSIII), SuperScript IV (SSIV), WarmStart  RTx (WS RTx) or, UltraScript 2.0 (US 2.0), influences
nucleotide misincorporation rates and the variant allele frequency (VAF) read-out of the m1acp3-assay,
although VAF remains consistent across biological replicates of input RNA of the colorectal cancer
(CRC) cell line HCT116 wildtype clone 1 (WT[1]), or HCT116 with  TSR3 gene knockout clone 1
(TSR3[KO 1]).  c, PCR replicates of WT[1] and TSR3[KO 1] cDNA, shows consistent readout.  d,
HCT116 WT[1] and TSR3[KO 1] RNA was mixed at fixed weight ratios (μg total RNA) prior to RT tog total RNA) prior to RT to
determine if the assay is quantitative for m1acp3  modification. e, The m1acp3 RT-PCR assay applied to
11 CRC cell lines, primary human umbilical vein endothelial cells (HUVEC) as a normal control and,
the blast-phase chronic myelogeous leukemia cell line K562 as a hypo-m1acp3Ψ), a modification positive control.  f i,
Polysomal fractionation and ii, sub-fraction m1acp3Ψ), a modification RT-PCR assay of the hypo-m1acp3Ψ), a modification cell  line
K562. In cells containing a mixture of +/- m1acp3Ψ), a modification modification, unmodified rRNA incorporates into
mature ribosomes and is enriched in the lower-order mono- and di-somes. g, Primer extension assay for
18S.1248.m1acp3Ψ), a modification modification in HCT116 WT[1] and TSR3[KO 1]. The helix 31 structural stop and
rRNA truncation via DNA cut oligo + RNase H treatment is used as internal load controls.
Supplementary Figure 3: 18S.1248.m1acp3Ψ is absolutely conserved in Eukarya
a,  Evolutionary conservation of 18S rRNA in the locus surrounding helix 31 in  Eukarya and select
Archaea  and  Eubacteria  species38,39.  Magenta  arrow  indicates  the  position  homologous  to
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human18S:1248.U.  b-d, The conserved secondary structure of helix 31 and its known modification
sites 38,40.
Supplementary Figure 4: Ribosomal molecular dynamics and modification modeling
The m1acp3Ψ), a modification  modification stabilizes the decoding peptidyl  (P-) site  via  a  hydrogen bond with the
universally conserved RPS16 (uS9) p.R146 residue. Whole ribosome molecular dynamics simulations
(MD) were ran for 25ns with 18S.1248.m1acp3Ψ), a modification or 18S.1248.U base. a, Root mean squared deviation
(RMSD) of MD atoms show the simulations stabilize after 5ns (with ~2Å RMSD), 20ns (highlighted)
was used for analysis. b, Root mean squared fluctuation (RMSF) of 18S rRNA i, adjacent to 18S.1248
and ii, in helix 31 shows 18S.1248. m1acp3Ψ), a modification is less flexible (0.5Å fluctuation) relative to unmodified
uridine.  c, Minimal  distance  between  m1acp3Ψ), a modification (3-carboxyl  oxygen)  or  uridine  (4-oxygen)  and the
closest guanidinium hydrogen of RPS16 p.R146 supports that acp3 is necessary to be within 3.5Å for
hydrogen  bonding  and  nucleotide  stabilization.  d,  20ns  simulation  of  showing  bonding  between
18S.1248.m1acp3Ψ), a modification and RPS16 p.R146 compared to the  e, cryo-EM structure with mRNA and P-site
tRNA28. We postulate that 18S.1248 acp3-modification is involved in coordinating RPS16 p.146 for P-
site tRNA positioning and contributes to the stability of the decoding core.
Supplementary Figure 5: RNA-seq and ribo-seq metrics
HCT116  WT[1-3]  versus  TSR3[KO]/[Het]  RNA-seq  and  ribo-seq  metrics.  a,  Differential  mRNA
expression  of  expressed  (reads  per  million  kilobase,  RPKMmRNA >0.1)  between  WT[1-3]  and
TSR3[KO]/[Het] clones.  b, Hierarchical  clustering of libraries  based on expressed genes.  Globally,
TSR3[Het 2] is more dissimilar to TSR3[KO 1,2] clones. c, MA-plot for mRNA expression highlighting
genes  in  the ‘KEGG_RIBOSOME’ and ‘RB_P107_DN.V1_UP’ gene sets  (see:  figure 3).  d i,  As a
quality control metric, the length distribution of mapped ribosome-protected fragments for each of the
two WT[1-3], and three  TSR3[KO]/[Het] biological replicates of ribo-seq libraries were plotted. The
TSR3[KO 3] biological replicate 2 (r2) library had a bi-modal read-length distribution, peaking at 22
and  28  nt  suggesting  incomplete  cycloheximide  treatment41 thus,  this  library  was  excluded  from
downstream expression and positional analyses. ii, Short (21-23 nt) ribosome fragments coincide with
ribosomes  stalled  in  the  rotated,  post  peptide-bond  state41.  TSR3[KO  1,3]  libraries  had  less  short
fragments  implying  m1acp3Ψ), a modification-deficient  ribosomes  have  a  lower  probability  of  being  in  the  rotated
transition  state  relative  to  WT  ribosomes.  e, Hierarchical  clustering  of  libraries  based  on  total
translation recapitulates mRNA clustering. f, Differential translation of ribo-seq expressed (RPKMRibo >
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0.1) genes. g, MA-plot for total translation, highlighting the ribosome and RB/E2F gene sets. h, P-site
occupancy  was  calculated  over  all  expressed  coding  sequences  (CDS).  Globally,  there  was  no
significant difference between P-site occupancy per codon in WT[1-3] in  TSR3[KO]/[Het] libraries.
Since 18S.1248.m1acp3Ψ), a modification is located at the P-site where initiation codon selection occurs, we tested if the
initiation AUG codon was differentially occupied between any genotypes. TSR3[Het 2] and TSR3[KO
1],  but not  TSR3[KO 3] have elevated AUG occupancy relative to WT clones supporting a slower
global initiation rate in those two samples.  i,  The P-site periodicity within each library showed the
majority  of  CDS  ribosomes  were  in-frame,  with  no  significant  difference  in  frame-shifting  upon
m1acp3Ψ), a modification  perturbation.  j,  The  log2 mRNA  fold-change  and  log2 translation  fold-change  (WT  /
TSR3[KO]/[Het]),  with  each  gene  size-scaled  by  RPKMmRNA.  RB/E2F  gene  sets  are  highlighted,
showing RP genes are more efficiently translated in TSR3[KO]/[Het] clones (all points below diagonal,
see also figure 3). Tukey HSD test was used for testing a statistical difference between group means (*
is p < 0.05, ** is p < 0.001 and *** is p < 0.0001)
Supplementary Figure 6: The RB/E2F transcriptional signature associated with TSR[KO]/[Het]
HCT116 WT[1-3] versus  TSR3[KO]/[Het] Gene Set Enrichment analysis (GSEA) for the oncogenic
signature  of  RB1,  RBL1 (p107).  a,  Gene  set  mRNA expression  is  enriched  specifically  in  genes
upregulated upon Rb1 and Rb1;p107 knockout (gene sets: RB_DN.V1_UP, RB_P107_DN.V1_UP). b,
Rb proteins are repressors of the E2F transcription factors. Target genes of E2F were highly enriched
upon TSR3[KO]/[Het]. c,  The translational output (ribo-seq signal) of genes upregulated in Rb1;p107
knockout remains increased but d, this gene set is translated less efficiently.
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Supplementary Table 1:
Accessions  of  DNA and  RNA sequencing  libraries  used  in  this  study.  18S.1248.U  variant  allele
frequency (VAF) is provided for each sample.
Supplementary Table 2:
Primers and guide RNA sequences.
Supplementary Table 3:
Significant (FDR q-value < 0.05) Gene Set Enrichment Analysis results for differential transcriptomics
in  HCT116  WT[1-3]  versus  TSR3[KO]/[Het]  with  the  Hallmarks,  C3  promoter  motif,  and  C6
oncogenic signatures gene sets.
Supplementary Table 4:
Significant (FDR q-value < 0.05) Gene Set Enrichment Analysis results with the C2 gene-ontology and
pathways gene sets for differential transcriptomics and translational efficiency in HCT116 WT[1-3]
versus TSR3[KO]/[Het] cell line and transcriptomics and proteomics in normo-m1acp3Ψ), a modification versus hypo-
m1acp3Ψ), a modification CPTAC-CRC tumors.
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Materials & Methods
Ribosomal sequence alignment and variant allele frequency calculations
DNA and RNA-seq libraries used in this study were prepared via poly-A selection to enrich for the
~5% of mRNA from total RNA. Since rRNA is ~80% of cellular RNA it invariably ‘contaminates’
RNA-seq libraries. Typically, poly-(A) RNA-seq libraries contain 3.55% (+/- 0.685, 95% CI, CRC I
cohort, N = 66) of total reads aligned to rDNA. A complete list of library accessions used in this study
is available in  table S142–45.
Libraries were aligned to the  hgr1 reference rDNA sequence10 with  bowtie2  (v.  2.3.5.1, command:
`bowtie2  --very-sensitive-local  -x  hgr1  -1  <read1.fq.gz>  -2  <read2.fq.gz>`)46.  For  each  cohort  of
libraries, a genomic variant call format (GVCF) was created with bcftools (v. 1.9, command: `bcftools
mpileup -f hgr1.fa –max-depth 10000 -A -min-BQ 30 -b <bam.file.list>`)47.
GVCF files were processed in R by custom scripts to calculate variant allele frequency (VAF). VAF is
defined as 1 – reference allele frequency (reference allele depth of coverage / total depth of coverage)
(scripts available at https://www.github.com/ababaian/crown)
The threshold to define hypo-modification of an RNA base (including 18S.1248.m1acp3Ψ), a modification) was defined
as three standard deviations below average VAF of the normal samples within the same cohort (false
discovery rate = 0.00135) when available. Fixed formalin paraffin embedded (FFPE) libraries in TCGA
were negative for 18S.1248.m1acp3Ψ), a modification, 28S.1321.m1A and 28S.4532.m3U modification signatures and
excluded from further analysis. In the CPTAC-CRC cohort (normal RNA-seq is unavailable), hypo-
m1acp3Ψ), a modification and normo-m1acp3Ψ), a modification was defined by the lower (<25%) and upper (>75%) quantiles of samples
within a batch.
Transcriptome and translatome alignment, assembly and differential expression
RNA-seq reads were aligned to hg38 (GRCh38) reference genome with tophat2 (v.2.0.14)48. Individual
transcriptome assemblies for HCT116 [WT 1-3], [KO 1,2] and [Het 2] libraries were generated with
stringtie (v 2.0)49, and then all merged together with the human gencode basic gene annotation (v. 31)50
ultimately yielding the hct116_gencode.v31 reference gene set. 
To generate a single-copy reference transcriptome for ribo-seq analysis of HCT116, isoform-specific
quantification of gene expression was performed on the hct116_gencode.v31 gene set with `stringtie -G
hct116_gencode.gtf`.  For  each  gene  with  non-zero  expression  (>10 unique  reads),  the  one  highest
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expression isoform (average expression from each clone) was chosen as the reference transcript for that
gene.
For ribo-seq alignment, after read adapter trimming and alignment to hgr1 as above, unmapped reads
were  aligned  against  a  containment  file  containing  human  tRNA,  mtDNA,  snoRNA,  snRNA and
miRNA  sequences.  Reads  remaining  unmapped  were  then  aligned  to  hg38 and  the
hct116_transcriptome with STAR aligner (v. 2.5.2b, command: `STAR --genomeDir hg38 --readFilesIn
<input.fq>  --sjdbFileChrStartEnd  hg38/sjdbList.out.tab  --outFilterMultimapNmax  10  --
outFilterMismatchNmax 5 --outFilterMatchNmin 15 --alignSJoverhangMin 5 --seedSearchStartLmax
20  --outSJfilterOverhangMin  30  8  8  8  --quantMode  TranscriptomeSAM`)51.  Transcriptome aligned
Ribo-seq data was analyzed in R (v. 3.5.1) using the riboWaltz package (v. 1.1.0)52.
Gene-level expression and total translation was quantified with the  DEseq253 R package using  hg38
aligned  bam  files  and  the  hct116_gencode.v31 reference  gene  set.  Translational  efficiency  was
calculated per genotype as log2( Ribo-seq GeneRPKM / RNA-seq GeneRPKM).
Gene expression and translation differences were calculated by Gene Set Enrichment Analysis (GSEA,
v.4.0.0)54 with `-permute gene_set -nperm 5000` and standard parameters. Transcriptomic GSEA was
performed using the MSigDB55 (v 7.0): hallmark, C2 pathways, C3 motif search, and C6 oncogenic
signatures gene sets. Translatomic and proteomic GSEA was performed with C5 Gene Ontology (GO)
gene set.
All  bioinformatic  analyses  were  scripted  for  reproducibility  and  are  available  at
https://www.github.com/ababaian/crown.
HCT116 cell culture and TSR3 knockout
The colorectal carcinoma cell line HCT116 (CCL-247, ATCC, Manassas, VA) was cultured in DMEM 
media (#36250, STEMCELL Technologies, Vancouver, Canada) supplemented with 10% fetal bovine 
serum (F1051, Invitrogen, Waltham, MA).
To generate  TSR3 knockouts,  105 HCT116 cells were transfected with 10 nmol of one of three TSR3
targeting Alt-R CRISPR-Cas9 ribonucleoproteins or non-targeting controls (table S2) by manufacturer's
protocol (1081059, Integrated DNA Technologies (IDT), Coralville, IA). After 24 hours, single cells
from each treatment  group were isolated by limiting dilution and confirmed to be 1 cell  /well  by
microscopy. Single cell clones were expanded to 5x105 cells at which point half the culture was frozen
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(culture media + 10% DMSO) and half were processed for RNA. TSR3 knockouts were genotyped by
RNA-seq and functional knockout was confirmed by three independent m1acp3Ψ), a modification assays (figure 3, S2).
Cell lines and clonal isolates were tested to be free of mycoplasma contamination by DAPI staining and
microscopy and with LookOut Mycoplamsa Detection Kit (MP0035, MilliporeSigma, Burlington, MA)
by manufacturer’s protocol.
RNA isolation and RNA-seq
Cells for RNA extraction were lysed directly in TRIzol reagent (15596-018, Invitrogen), spun 5 min at
12,000 x g to pellet fat and nuclear DNA and then frozen at -80°C. RNA extraction was carried out by
manufacturer’s  protocol.  RNA  quality  was  assessed  via  2%  denaturing  RNA  agarose  gel
electrophoresis  (heat  treated,  95°C  for  5  minutes  in  1.5x  formamide  loading  buffer56)  and
concentration/purity assessed by spectrophotometer (NanoDrop 2000, ThermoFisher, Waltham, MA).
RNA quality for RNA-seq library preparation had a >9.9 RIN score measured by Bioanalyzer 2100
(Agilent, Santa Clara, CA).
RNA-seq library  preparation  and sequencing  was  performed by the  BC Cancer  Genome Sciences
Centre, Vancouver, Canada. Briefly, 75-bp stranded and paired-end poly-(A) RNA-seq libraries were
prepared with NEBNext poly(A) mRNA magnetic isolation module (E7490L, New England BioLabs
(NEB), Ipswich, MA), Maxima H minus First Strand cDNA synthesis kit (K1652, Thermo-Fisher), and
NEBNext Ultra II directional RNA second strand synthesis (E7771, NEB). The total RNA-seq libraries
were prepared in parallel but without poly-(A) selection and only 2x PCR cycles (for adapter ligation).
Libraries were sequenced on a HiSeq 2500 (Illumina, San Diego, CA). 
Assays for 18S.1248.m1acp3Ψ modification
Primer extension was performed with 1 µg of total RNA, incubated with 2 pmol of PE_1248_BLOCK
(IDT) primer and 2U of RNase H (18021-014, Invitrogen) or mock enzyme treatment at 37°C for 20
min followed by heat inactivation at 65°C for 10 min. SuperScript III reverse transcriptase (18080044,
lot #2042663, Invitrogen) and the flourophore labeled  PE_1248_FAM primer were added for primer
annealing and RT (1h at  50°C) as  described by Schuster  and Bertram57.  Labeled cDNAs were re-
suspended in 1.5x formamide loading buffer and heated to 95°C for 3 min to eliminate secondary
structures56.  Samples  were separated on a 2% agarose gel  at  114 V for 3h at  4°C or  on a  12.5%
polyacrylamide gel at 45 mA for 2.5h in 1x TBE. After migration, the gel was visualized with the
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Typhoon FLA 9500 laser scanner (FAM filter, 50 µm pixel and 450 V unless otherwise noted, GE
Healthcare, Chicago, IL). 
The  RT-PCR  1248.m1acp3Ψ), a modification  assay  was  performed  with  1  ug  of  DNase  treated  (AM1907,  lot
#00733051,  Invitrogen)  RNA after  total  RNA quality  was  assessed  by  denaturing  agarose  gel
electrophoresis56.  RT  reaction  was  carried  out  with  SuperScript  III  (Invitrogen),  SuperScript  IV
(18090010,  lot  #00721480,  Invitrogen),  UltraScript  2.0  (PB30.31-10,  lot  #PB130614-01-5,  PCR
Biosystems, Wayne PA) and WarmStart RTx (M0380L, lot #0061705, NEB) by each manufacturer’s
protocol with minor modifications. RT reactions were carried out with a random hexamer primer only,
and not poly(T) oligos. cDNAs were diluted five-fold and used as template for PCR (30 cycles: 94°C
for 30 s, 55°C for 30 s, 72°C for 30 s) with macp_F1 and macp_R1 primers (table S2). Amplicons were
digested with HinFI (R0155S, New England BioLabs) (25°C for 5 sec, 37°C for 90 min, 80°C for 20
min). Samples were separated on a 2.25% agarose gel in 1x TBE at 200 V for 45 min at 4°C. After
migration, the gel was post-stained in 1x GelRed (41003, Biotium, Fremont CA) for 30 min. Gels were
visualized by UV transillumination, captured in gray scale with a digital camera and pseudo-colored in
ImageJ58 (v 1.52h, Lookup table > Fire) which retains the original pixel intensity values but highlights
band-intensity visualization.
Ribosome foot-printing
Ribosome foot printing (ribo-seq) was performed as previously described59 with minor modifications.
For cell  harvesting, the culture medium was aspirated, cells  were washed twice with ice-cold PBS
supplied with 100 μg total RNA) prior to RT tog/ml cycloheximide and plates were flash-frozen in liquid nitrogen. For cell lysis,
the plates were placed on wet ice and 400 µl of mammalian polysome buffer (MPB) [20 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 5 mM MgCl2, with 1 mM DTT and 100 μg total RNA) prior to RT tog/ml cycloheximide, 1% (vol/vol)
Triton X-100, 25 U/ml Turbo DNase ( AM2238, Invitrogen) was dripped onto the plates. Cells were
scraped, the lysate was collected to fresh 1.5 ml tube, passed ten times through a 26-gauge needle,
cleared by centrifugation at 20,000 x g for 10 min, flash-frozen in liquid nitrogen and stored at −80 °C
until further use. For isolation of ribosome-protected RNA fragments, 240 μg total RNA) prior to RT tol of the lysate was digested
with 6 μg total RNA) prior to RT tol of RNase I (AM2294, 100 U/μg total RNA) prior to RT tol, Invitrogen) at room temperature with rotation. After 45 min 8
μg total RNA) prior to RT tol  of  SUPERase-In  (20  U/μg total RNA) prior to RT tol,  AM2694,  Invitrogen)  was  added  to  reaction  and  passed  through
MicroSpin S-400 HR columns (27-5140-01, GE Healthcare) equilibrated with mammalian polysome
buffer. RNA was extracted from the flow-through using Trizol LS (10296-010, Invitrogen) followed by
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depletion of ribosomal RNA fragments with the RiboZero Kit (MRZH11124, Illumina). Ribosome-
protected  RNA fragments  were  loaded  onto  denaturing  17%  urea-PAGE  gel  (EC-829,  National
Diagnostics) and gel area ranging from 27 nt to 30 nt, defined by corresponding RNA markers, was cut
out. Purified RNA fragments were subjected to library generation using 3′ adapter 4N-RA3, 5′ adapter
OR5-4N,  RT primer  RTP and  PCR primers  RP1  (forward  primer)  and  RPI1-15  (reverse  primers,
containing barcodes). Libraries were sequenced on a HiSeq 4000 device (Illumina). 
Polysome Fractionation
Polysome fractionation was performed as previously described60, with minor modifications. Media was
removed from 100 mm dish with ~107 cells and washed with ice-cold ddH2O containing 100 μg total RNA) prior to RT toM CHX.
All  subsequent  steps were performed chilled at  4°C or on ice.  After  ddH2O aspiration,  cells  were
incubated for 30 min in 450 μg total RNA) prior to RT toL of hypotonic lysis buffer [0.1x polysome base buffer (PBB), 150 mM
KCl,  20 mM Tris-HCl  pH 7.4,  15 mM MgCl2 in  ddH2O; with  1% Triton-X 100 and 1x protease
inhibitor (4693132001, MilliporeSigma). After confirming >95% free nuclei with a hemocytometer,
nuclei were pelleted by centrifugation at 1,800 x g for 5 minutes. Cytoplasmic fraction was separated
from mitochondria  by centrifugation  at  10,000 x g for  5  minutes.  300 μg total RNA) prior to RT toL cytoplasmic  lysate  was
layered atop at 7-45% sucrose gradient (Gradient Master, BioComp, Fredericton, Canada) in 1x PBB.
Gradients were ultra-centrifuged at 221,600 x g for 2 hours at 4°C (SW-41Ti rotor, 331362, Beckman
Coulter,  Brea,  CA). Gradients  were fractionated (Piston Fractionator,  BioComp) into 20 x 300 μg total RNA) prior to RT toL
fractions  with  in-line  UV-scanning  at  254  nm.  Fractions  were  immediately  frozen  at  -20°C  for
subsequent RNA extraction.
Ribosomal molecular dynamics simulations
All molecular dynamics (MD) simulations were performed as described in Girodat et al. 201961. In
brief, 80S ribosome models were derived from available human Cryo-EM structures with a resolved
18S.1248.m1acp3Ψ), a modification (PDB: 6EKO for E-site tRNA and 6OLE for A/P and P/E tRNA) 27,28.
For simulations lacking  m1acp3Ψ), a modification modifications, the base was converted to uracil.  Each system was
protonated with the psfgen package in VMD 1.9.3, and only e-nitrogen for histidine were protonated62.
Each system was solvated with a 10Å TIP3P water  box with a concentration of 7mM MgCl2  and
100mM KCl using the  solvate and  autoionize packages,  respectively62.  All  minimizations  and MD
simulations  were  performed  with  NAMD 2.1.2  using  CHARMM  36 standard  parameters63–65 and
modified nucleic acid parameters from Xu et al. 201666. 
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Each system underwent a steepest descent minimization of water for 10,000 steps then water and ions
for 100,000 steps twice followed by minimization of nucleic acid and protein for 50,000 steps and
finally the whole system for 100,000 steps. After minimization all systems were equilibrated to 300 and
350 K for 150 ps. Coordinates of the 350 K equilibration in conjunction with velocities from the 300 K
equilibration were used as initial parameters for the MD simulation. Each system was simulated for
~20ns. Energy contributions of  18S.1248.m1acp3Ψ), a modification or  18S.1248.U were determined with the  NAMD
Energy package65.
Statistics
Statistical analysis was performed in R (v 3.5.1). Differences in variant allele frequency (VAF) between
tumor and normal patient samples was two-tailed, paired Student’s T-test with degrees of freedom one
less than reported  n. Bonferonni multiple-testing correction was applied when screening for changes
across 18S and 28S nucleotides. Error bars on boxplots are quantiles. Differential gene expression and
translation was tested with DEseq253 with Benjamini-Hochberg multiple testing correction at an alpha
of  0.05.  Multi-group comparisons  between HCT116 WT[1],[2],[3]  and  TSR3[KO 1],[KO 3],[Het2]
ribo-seq  were  performed  with  one-way  ANNOVA,  followed  by  Tukey’s  Honestly  Significant
Differencce (HSD) test if indicated.
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